Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indian Clinical Research Industry Divided Over Mandatory Registration Of Clinical Trials From June 15

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - As the June 15 deadline approaches for India's mandatory registration of clinical trials in a publicly accessible library, the industry is bracing itself to put trial details online with mixed reactions

You may also be interested in...



Top Indian CROs Unite On Centralized Biometric Database Covering Trial Volunteers

MUMBAI - Leading Indian clinical research organizations have united to create a centralized biometrics database in what is seen as the first ever concerted attempt to avoid duplication of volunteers in various clinical trials within the "wash-out period.

Top Indian CROs Unite On Centralized Biometric Database Covering Trial Volunteers

MUMBAI - Leading Indian clinical research organizations have united to create a centralized biometrics database in what is seen as the first ever concerted attempt to avoid duplication of volunteers in various clinical trials within the "wash-out period.

India Floats Draft Guidelines For Mandatory Registration Of CROs

MUMBAI - In a step aimed at tightening laws governing clinical research in India, the Central Drug Standards Control Organization has released its draft guidelines for registration of clinical research organizations in India. The guidelines have been approved by the Drug Technical Advisory Board but stakeholders will be consulted before the Drug And Cosmetics Rules could be amended to incorporate the new framework

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071746

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel